HSBC Turns More Bullish on Amgen (AMGN) into 2026
Affected assets and topics
Why it matters
HSBC has upgraded its price target for Amgen Inc. (AMGN) to $425 from $381, maintaining a Buy rating as part of its positive outlook for the pharmaceutical sector through 2026. This indicates a strong belief in Amgen's future performance and potential growth.
Expected market reaction
Market impact analysis based on bullish sentiment with 82% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- openai-gpt-4o-mini
- Analysis version
- openai-gpt-4o-mini
- Article id
- 23683
Original source
Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on December 17, 2025. Analysis and insights provided by AnalystMarkets AI.